Table 2.
Chemotherapy and hormonal regimens for patients prior to and after undergoing secondary cytoreductive surgery (SCRS) (N=41)
| Regimen or agent given prior to SCRS | n (%) |
| Chemotherapy | |
| Paclitaxel | 4 (9.8) |
| Platinum/taxane | 4 (9.8) |
| Carboplatin1 | 2 (4.9) |
| Pegylated liposomal doxorubicin | 1 (2.4) |
| High dose chemotherapy with peripheral stem cell transplant | 1 (2.4) |
| Ifosfamide and etoposide | 1 (2.4) |
| Vinorelbine | 1 (2.4) |
| Hormonal treatment | |
| Letrozole | 1 (2.4) |
| Tamoxifen | 1 (2.4) |
| Regimen or agent given after SCRS | n (%) |
| Chemotherapy | |
| Platinum + taxane | 8 (19.5) |
| Platinum + pegylated lipopsomal doxorubicin | 2 (4.9) |
| Pegylated liposomal doxorubicin | 2 (4.9) |
| Taxane, single agent | 2 (4.9) |
| Topotecan | 2 (4.9) |
| Platinum + taxane + bevacizumab | 1 (2.4) |
| Platinum, single agent | 1 (2.4) |
| Ifosofamide + etoposide | 1 (2.4) |
| Hexamethylmelanamine | 1 (2.4) |
| Gemcitabine | 1 (2.4) |
| Chemotherapy, not otherwise specified | 1 (2.4) |
| Hormonal treatment | |
| Letrozole | 5 (12.2) |
| Tamoxifen | 4 (9.8) |
| Anastrozole | 1 (2.4) |
| Leuprolide acetate | 1 (2.4) |
1
One patient who received carboplatin also received concurrent tamoxifen.